A Phase 2 interventional study of Petrelintide and Enicepatide in Obesity or Overweight, sponsored by Hoffmann-La Roche. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Obesity by Hoffmann-La Roche — 8 open to participants now, 12 under way, 7 of them phase 3. Obesity · Hoffmann-La Roche.
Among the 21 studies in Obesity by Hoffmann-La Roche, this one is the 7th largest by planned enrollment, is one of 8 that started in 2026, is one of 7 in phase 2, reaches primary completion later than 4 of the 11 other live ones, and was the 16th registered.
11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
Browse Obesity studies →8 of the 21 studies in Obesity by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in United States
Ages 18+
Hoffmann-La Roche · Sites in United States, Taiwan, United Kingdom
Ages 40+
Hoffmann-La Roche · Sites in United States
Ages 18+
Hoffmann-La Roche · Sites in China
Ages 18+
Hoffmann-La Roche · Sites in United States, Argentina, Australia and 19 more countries
Ages 18+
By country, each count listing its studies:
Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 486 is above the median of 67 across 9,016 interventional studies indexed under Obesity.
Median enrollment 300 across the 21 interventional studies. Of the 9 that completed or were terminated, 1 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
3 of the studies in Obesity by Hoffmann-La Roche that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06982131Hoffmann-La RocheA Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants | 2026-12-07 |
| NCT07499050Hoffmann-La RocheA Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or Overweight | 2027-01-09 |
| NCT07589686Hoffmann-La RocheA Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight | 2027-11-12 |
Add all 3 to your calendar (.ics) → With an account.
Among the 21 studies in Obesity by Hoffmann-La Roche, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the safety and efficacy of the co-administration of petrelintide and enicepatide compared with placebo, petrelintide monotherapy, and enicepatide monotherapy in participants with obesity or overweight with at least one weight-related comorbidity.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Combination Product: Petrelintide · Combination Product: Enicepatide
Combination Product: Petrelintide · Combination Product: Enicepatide
Combination Product: Petrelintide · Combination Product: Enicepatide
Combination Product: Enicepatide · Combination Product: Petrelintide-matching Placebo
Combination Product: Petrelintide · Combination Product: Enicepatide-matching Placebo
Combination Product: Petrelintide-matching Placebo · Combination Product: Enicepatide-matching Placebo
Petrelintide will be administered subcutaneously to participants once weekly
Also known as: RO7895515, ZP8396
Enicepatide will be administered subcutaneously to participants once weekly
Also known as: RO7795068, CT-388, RG6640
Matching placebo to Petrelintide will be administered subcutaneously to participants once weekly
Matching placebo to Enicepatide will be administered subcutaneously to participants once weekly
Percentage Change in Body Weight between Arms 1 and 6
Time frame: From Baseline to Week 40
Percentage Change in Body Weight between Arms 2, 3 and Arm 6
Time frame: From Baseline to Week 40
Percentage Change in Body Weight between Arms 1, 2, 3 and Arms 4, 5
Time frame: From Baseline to Week 40
Percentage of Participants Achieving Body Weight Loss
Time frame: From Baseline to Week 40
Change in Body Weight (kilograms [kg])
Time frame: From Baseline to Week 40
Change in Body Mass Index (kilograms per square meter [kg/m²])
Time frame: From Baseline to Week 40
Change in Waist Circumference (centimeter [cm])
Time frame: From Baseline to Week 40
Change in Hemoglobin A1c (HbA1c) (percentage-points)
Time frame: From Baseline to Week 40
Change in Fasting Insulin
Time frame: From Baseline to Week 40
Change in Fasting Glucose
Time frame: From Baseline to Week 40
Change in Systolic Blood Pressure
Time frame: From Baseline to Week 40
Change in Diastolic Blood Pressure
Time frame: From Baseline to Week 40
Change in High-Density Lipoprotein (HDL) Cholesterol
Time frame: From Baseline to Week 40
Change in Low-Density Lipoprotein (LDL) Cholesterol
Time frame: From Baseline to Week 40
Change in Very-Low-Density Lipoprotein (VLDL) Cholesterol
Time frame: From Baseline to Week 40
Change in Non-HDL Cholesterol
Time frame: From Baseline to Week 40
Change in Total Cholesterol
Time frame: From Baseline to Week 40
Change in Free Fatty Acids
Time frame: From Baseline to Week 40
Change in Triglycerides
Time frame: From Baseline to Week 40
Change in High-Sensitivity C-reactive Protein (hsCRP)
Time frame: From Baseline to Week 40
Number of Participants with Adverse Events (AEs)
Time frame: From Baseline to Week 40
No study locations are listed for this record.
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Start is estimated for Nov 2026; primary completion for Nov 2027, 11 months later.
Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's planned 11 months is close to that.
Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.
Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, on Nov 3, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Petrelintide · Enicepatide